Alcoholic Hepatitis: A Multicenter, Observational Study by the TREAT Consortium
Status: | Active, not recruiting |
---|---|
Conditions: | Hepatitis |
Therapuetic Areas: | Immunology / Infectious Diseases |
Healthy: | No |
Age Range: | 21 - Any |
Updated: | 8/9/2018 |
Start Date: | June 2013 |
End Date: | July 2019 |
To conduct a prospective, multicenter, observational study of patients with
well-characterized alcoholic hepatitis (AH) and frequency matched individuals (by age,
gender, and race) with comparable history of alcohol consumption but no clinical evidence of
liver disease (controls). At the end of the study, a robust clinical information, central
bio-repository will be developed from both cases and controls.
well-characterized alcoholic hepatitis (AH) and frequency matched individuals (by age,
gender, and race) with comparable history of alcohol consumption but no clinical evidence of
liver disease (controls). At the end of the study, a robust clinical information, central
bio-repository will be developed from both cases and controls.
CASES: Heavy drinkers with alcoholic hepatitis
Inclusion criteria
1. The diagnosis of AH will be established on published criteria this is based on:
1. Average daily ethanol consumption of > 40 grams/day for women and > 60 grams/day for
men for a minimum of 6 months and within the 6 weeks prior to study enrolment.
Judgment regarding daily and yearly alcohol use will be made by the site investigator
2. Clinical evaluation and appropriate laboratory testing as defined by total bilirubin >
2 mg/dL and AST > 50 U/L. When the diagnosis of AH remains in question, a liver biopsy
(if clinically feasible and that subject has no contra-indications) will be required.
3. Subjects with HBV, HCV and/or HIV will be eligible for enrollment
Exclusion criteria
1. Evidence of other liver diseases such as autoimmune or drug-induced
2. Significant concomitant medical illnesses such as uncontrolled congestive heart
failure or COPD, or multiorgan failure
3. Abstinence of alcohol use > 6 weeks immediately preceding enrollment
4. Hemochromatosis
5. Wilson Disease
6. Active intravenous drug use
CONTROLS: Heavy drinkers without alcoholic hepatitis
Inclusion criteria
1. Average daily ethanol consumption of > 40 grams /day for women and > 60 grams/day for
males for a minimum of 6 months and within the 6 weeks prior to study enrollment. In
addition, heavy drinkers who have just become abstinent within prior 2 weeks are
eligible to be enrolled. Judgment regarding daily and yearly alcohol use will be made
by the site investigator
2. AST and ALT ≤ 50 and total bilirubin levels within normal range. If bilirubin is
increased due to a suspected Gilbert's Syndrome, patient may be enrolled if the direct
bilirubin is within normal limits
Exclusion criteria
1. Evidence of liver disease
2. Significant concomitant medical illnesses such as uncontrolled congestive heart
failure or COPD, or multiorgan failure
3. Abstinence of alcohol use > 2 weeks immediately preceding enrollment
4. Hemochromatosis
5. Wilson Disease
6. Active intravenous drug use
7. Prior history of known alcoholic liver disease
8. Presence of hepatosplenomegaly from the physical examination/radiographic imaging or
stigmata of liver disease
We found this trial at
2
sites
Rochester, Minnesota 55905
Principal Investigator: Vijay Shah, MD
Phone: 507-284-2698
Click here to add this to my saved trials
Richmond, Virginia 23298
(804) 828-0100
Principal Investigator: Arun J Sanyal, MD
Phone: 804-628-4395
Virginia Commonwealth University Since our founding as a medical school in 1838, Virginia Commonwealth University...
Click here to add this to my saved trials